RxDoctor Payments Data

Dong-Hong Shong, MD

Internal Medicine · Flushing, NYNPI 1659353068

Payments from drug & device makers

$3,358in general payments, 2019–2025

Across 53 payments — averaging $63.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Gilead$880
  • Novo Nordisk$375
  • AstraZeneca$223
  • Johnson & Johnson$109
  • Foundation Medicine, Inc.$100

What the payments were for

  • Food & beverage$3,352100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)24$1,671
Gilead17$880
Novo Nordisk3$375
AstraZeneca6$223
Johnson & Johnson2$109
Foundation Medicine, Inc.1$100

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,358 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$580,220
Medicare patients
371
Services billed
8,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl1,468$616,073
JardianceEmpagliflozin368$328,484
EliquisApixaban316$277,940
FarxigaDapagliflozin Propanediol285$251,019
VemlidyTenofovir Alafenamide146$235,611
XareltoRivaroxaban243$213,013
JanuviaSitagliptin Phosphate224$202,548
ProliaDenosumab89$151,543
Diclofenac Epolamine280$124,361
RybelsusSemaglutide81$113,583
CreonLipase/Protease/Amylase111$113,203
JanumetSitagliptin Phos/Metformin Hcl159$100,899
LinzessLinaclotide147$80,652
TradjentaLinagliptin83$63,267
ShingrixVaricella-Zoster Ge/As01b/Pf389$56,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy, Viread$880$255,521162 claims
AstraZenecaFarxiga$223$251,019285 claims
AbbVieCreon, Linzess, Restasis$1,671$236,962323 claims
Johnson & JohnsonXarelto$109$213,013243 claims
Novo NordiskRybelsus, Ozempic$375$160,170130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →